DIPYRIDAMOLE Drug Patent Profile
✉ Email this page to a colleague
When do Dipyridamole patents expire, and when can generic versions of Dipyridamole launch?
Dipyridamole is a drug marketed by Chartwell Injectable, Dr Reddys, Eugia Pharma Speclts, Fresenius Kabi Usa, Hikma, Hospira, Ani Pharms, Barr, Genus, Glenmark Generics, Impax Labs, Oxford Pharms, Purepac Pharm, Rising, Watson Labs, and Zydus Pharms Usa Inc. and is included in twenty-two NDAs.
The generic ingredient in DIPYRIDAMOLE is dipyridamole. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dipyridamole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dipyridamole
A generic version of DIPYRIDAMOLE was approved as dipyridamole by BARR on October 3rd, 1990.
Summary for DIPYRIDAMOLE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 22 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 148 |
Clinical Trials: | 79 |
Patent Applications: | 4,253 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DIPYRIDAMOLE |
What excipients (inactive ingredients) are in DIPYRIDAMOLE? | DIPYRIDAMOLE excipients list |
DailyMed Link: | DIPYRIDAMOLE at DailyMed |
Recent Clinical Trials for DIPYRIDAMOLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Guo-Qing Jiang | N/A |
Clear Creek Bio, Inc. | Phase 2 |
Rutgers, The State University of New Jersey | Phase 3 |
Pharmacology for DIPYRIDAMOLE
Drug Class | Platelet Aggregation Inhibitor |
Physiological Effect | Decreased Platelet Aggregation |